CAMBRIDGE, Mass., July 23, 2019 /PRNewswire/ --áInfinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, July 30, 2019 at 8:00 a.m. ET to review its second quarter 2019 financial results and provide an update on the company.
A live webcast of the conference call can be
About Infinity and IPI-549
Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-1 is an ongoing Phase 1/1b study evaluating IPI-549 as a monotherapy and in combination with Opdivo« (nivolumab) in approximately 225 patients with advanced solid tumors including patients refractory to anti-PD-1 therapy. Infinity's guidance is to initiate MARIO-275, a global, randomized, combination study of IPI-549 combined with Opdivo in I/O na´ve urothelial cancer patients in 2Q19, as well as to initiate MARIO-3, the first IPI-549 combination study in front-line advanced cancer patients in 2H19. MARIO-3 will evaluate IPI-549 in combination with Tecentriq« and Abraxane« in front-line TNBC and in combination with Tecentriq and Avastin« in front-line RCC. With the addition of MARIO-275 and MARIO-3 to the ongoing MARIO-1 study, Infinity will be evaluating IPI-549 in the anti-PD-1 refractory, I/O-na´ve and front-line settings in a total of ~500 patients. For more information on Infinity, please refer to Infinity's website atáwww.infi.com.
Contact:Stephanie Ascher, Stern Investor Relations, Inc.212-362-1200 or Stephanie@sternir.com
View original content:http://www.prnewswire.com/news-releases/infinity-announces-the-date-of-its-second-quarter-2019-financial-results-conference-call-and-webcast-300889103.html
SOURCE Infinity Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!